Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement over standard of careNovartis plans to submit to health authorities globally starting in early 2026Ianalumab has potential to become first targeted treatment for this autoimmune disease with significant unmet need Basel, January 16, 2026 – Novartis today announced that the U ...